natgillin/translations-raw huggingface dataset:
A salt of the compound of formula [I] which salt is selected from the hydrogen adipate salt, the hydrogen malonate salt, the hydrogen fumarate salt, the hydrogen succinate salt, the benzene sulfonate salt, the hydrogen maleate salt and the salicylate salt of the compound of formula [I]. 
Sol spoja formule [I] sol koja je odabrana između soli vodikovog adipata, vodikove malonatne soli, vodikove fumaratne soli, vodikove sukcinatne soli, benzen-sulfonatne soli, vodikove maleatne soli i salicilatne soli spoja formule [I].
The method of any one of clauses 46-61, wherein the pluripotent cells are cultured in the presence of vascular endothelial growth factor (VEGF) and/or bone morphogenic protein 4 (BMP-4). 
Postupak u skladu s patentnim zahtjevom 12, naznačen time što se pluripotentne stanice uzgaja u prisutnosti čimbenika rasta vaskularnog endotela (VEGF) i/ili koštanog morfogenetskog proteina 4 (BMP-4).
The solid oral extended release pharmaceutical dosage form of anyone of items 60, 62, 64, 66, 68, 71-78, 81, 84 and 85, wherein the extended release matrix formulation after having been stored at 25 °C and 60 % relative humidity (RH) for at least 1 month contains an amount of the at least one active agent in % (by wt) relative to the label item of the active agent for the extended release matrix formulation that deviates no more than about 10 % points from the corresponding amount of active agent in % (by wt) relative to the label item of the active agent for the extended release matrix formulation of a reference formulation prior to storage. 
Oralni farmaceutski oblik doziranja u krutom stanju sa produljenim otpuštanjem prema bilo kojem od zahtjeva 1 do 16, naznačen time da formulacija matrice sa produljenim otpuštanjem nakon što je pohranjena na 25 *C 1 60 % relativne vlažnosti (RH) tijekom najmanje 1 mjeseca sadrži količinu od najmanje jednog aktivnog sredstva u % (težinski) vezano uz deklaracijski zahtjev aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem tako da odstupanje nije veće od oko 10 % točaka u odnosu na odgovarajuću količinu aktivnog sredstva u % (težinski) relativno prema deklaracijskom zahtjevu aktivnog sredstva za formulaciju matrice s produljenim otpuštanjem referentne formulacije prije pohranjivanja.
The method according to Claim 8, wherein (1) the herbicidal sulfonylurea compound or its salt and (2) the polyoxyalkylene alkyl ether phosphate or its salt are applied in a weight ratio of from 13:1 to 1:10,000, and (2) the polyoxyalkylene alkyl ether phosphate or its salt and (3) the salt are applied in a weight ratio of from 500:1 to 1:5. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time, da (1) spoj sulfonil urjea herbicida ili sol istog i (2) polioksialkilen alkil eter fosfat ili sol istog su primjenjeni u masenom omjeru od 13:1 do 1:10,000 te (2) polioksialkilen alkil eter fosfat ili sol istog i (3) sol su primjenjene u masenom omjeru od 500:1 do 1:5.
A method for producing an isolated IL-23p19 antibody according to any of claims 1-3, comprising providing a host cell or non-human transgenic animal or transgenic plant or plant cell capable of expressing in recoverable amounts said antibody. 
Postupak in vitro za proizvodnju izoliranog IL-23p19 antitijela prema bilo kojem od patentnih zahtjeva 1-7 1 10-14, naznačen time da osigurava stanicu domaćina ili neljudske transgene životinje ili transgene biljke ili biljne stanice pogodne za expresiju nadoknadive količine spomenutog antitijela.
A pharmaceutical composition according to any one of paras. 1 to 18, wherein, if arginine is present, the molar ratio of arginine to said HDAC inhibitor is at least 0.5. 
Farmaceutski sastav prema bilo kojem zahtjevu od 1 do 6, naznačen time, da je molarni odnos arginina prema spomenutom HDAC inhibitoru najmanje 0,5.
Evaporated to dryness, then re-dissolved in 1,2-dichloroethane (20 mL) and added to a suspension of 2-amino thiazole (25 mmol) and pyridine (30 mmol) in 1,2-dichloroethane (50 mL). 
Upari se do suha, potom ponovno otopi u 1,2-diklorostanu (20 ml) i doda u suspenziju 2-amino tiazola (25 mmol) i piridina (30 mmol) u 1,2-doikloretanu (50 ml).
A compound according to any of claims 1-3, or a pharmaceutically acceptable salt thereof for use as a medicament. 
Farmaceutski sastav prema bilo kojem od zahtjeva 1-15 za upotrebu kao lijek.
The pharmaceutical composition of claim 5, further comprising a therapeutic agent selected from an immunomodulatory agent, a hormonal agent, a chemotherapeutic agent, an anti-angiogenic agent, an apoptotic agent, a second antibody that binds to and inhibits an inhibitory KIR receptor, an anti-infective agent, a targeting agent and an adjunct compound. 
Oblik prema zahtjevu 31, koji dalje sadrži terapijsko sredstvo izabrano između imunomodulatornog sredstva, hormona, kemoterapijskog sredstva, anti-angiogeničnog sredstva, apoptotičnog sredstva, drugog protutijela koje veže 1 inhibira taj inhibitorni KIR receptor, anti-infektivnog sredstva, ciljnog sredstva ili dodatnog spoja.
The message controller as claimed in claim 1, wherein the processor is adapted to add or delete application functions, or change their sequence, in a modular manner. 
Kontroler poruka prema bilo kojem od prethodnih zahtjeva, pri čemu je procesor prilagođen da na modularan način doda ili ukloni aplikativne funkcije, ili da promijeni njihov redoslijed.
normalizing the migration time(s) to migration time indice(s) based on given standard migration time indice(s) of the standard; 
normaliziranja vremena migracije(a) prema indeksu(ima) vremena migracije standarda;
A kit of claim 6 for quantitative PCR analysis of a species specific target sequence in a food sample, said kit comprising a further set of primers and probes for the amplification and real-time detection of a sequence from the myostatin gene, said sequence being selected to allow for species specific amplification and/or detection. 
Pribor iz zahtjeva 6 za kvantitativnu PCR analizu ciljne sekvence specifične za vrstu u uzorku hrane, naveden pribor sadržeći daljnji set početnica 1 sondi za amplifikaciju 1 detekciju u stvarnom vremenu sekvence iz miostatin gena, navedena sekvenca bivajući odabrana zbog omogućavanja amplifikacije i/ili detekcije specifične za vrstu.
The method of claim 22, wherein the antibody selected in step (b) inhibits the binding of a HLA-c allele molecule having a Lys residue at position 80 to a human KIR2DL1 receptor, and the binding of a HLA-C allele molecule having an Asn residue at position 80 to human KIR2DL2/3 receptors. 
Postupak prema zahtjevu 22, gdje protutijelo izabrano u koraku (b) inhibira vezanje HLA-c alel molekule koja ima Lys ostatak na položaju 80, za humani KIR2DLI receptor, i vezanje HLA-C alel molekule, koja ima Asn ostatak na položaju 80, za humane KIR2DL2/3 receptore.
represents C1-C4-alkyl, preferably methyl or ethyl, are reacted in the presence of a base with compounds of the formula (VII) 
R? predstavlja C,-C,-alkil, poželjno metil ili etil, Teagira u prisutnosti baze sa spojem s formulom (VII)
Multiparticulates according to claim 4, wherein the plasticiser is a high molecular weight polyethylene glycol. 
Višečestični oblici prema patentnom zahtjevu 4, naznačeni time što je plastifikator polistilen glikol visoke molekularne težine.
mixing the granules obtained in step b with a composition comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid; and optionally adding further lubricant, wherein the mixture of step a does not comprise a salt of N-(8-(2-hydroxybenzoyl)amino) caprylic acid, and wherein said composition is in the form of a solid dosage form selected from the group consisting of a tablet, a capsule, and a sachet. 
C) miješanja granula_ dobivenih u koraku bo s pripravkom koji sadrži sol N-(8-(2- hidroksibenzoiljamino)kaprilne kiseline; i d) = izbornog dodavanja dodatnog maziva, gdje smjesa iz koraka a ne sadrži sol N-(8-(2-hidroksibenzoiljamino)kaprilne kiseline, te gdje je navedeni pripravak u obliku čvrstog oblika doziranja, kojeg se bira iz skupine koju čine tableta, kapsula, te vrećica.
The method of claim 18, wherein said parent bacterial strain is suitable for use as a starter culture, a probiotic culture, and/or a dietary supplement culture. 
Postupak prema zahtjevu 15, naznačen time da navedeni matični bakterijski soj je soj dobiven iz kulture koja je odabrana od starter kultura, probiotičkih kultura, te kultura dodataka prehrani.
Y is an optionally substituted phenyl, an optionally substituted pyridyl, or an optionally substituted [1,2,3]thiadiazolyl. 
X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
The biocompatible implant according to anyone of the preceding claims, wherein other biomolecules are present on a metal metal alloy or metal oxide surface of the implant, said biomolecules being selected from the group consisting of natural biomolecules, synthetic biomolecules, and recombinant biomolecules, cell attachment factors, biopolymers, blood proteins, enzymes, extracellular matrix proteins and biomolecules, growth factors and hormones, nucleic acids, receptors, synthetic biomolecules, vitamins, drugs, iphosphonates, biologically active ions, fluoride, and marker biomolecules. 
Biokompatibilni usadak u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što su druge biomolekule prisutne na metalnoj, metalnolegurnoj ili metalnooksidnoj površini usatka, gdje se navedene biomolekule bira iz skupine koju čine prirodne biomolekule, sintetske biomolekule, te rekombinantne biomolekule, čimbenici staničnog vezanja, biopolimeri, krvni proteini, enzimi, proteini i biomolekule izvanstaničnog matriksa, čimbenici rasta 1 hormoni, nukleinske kiseline, receptori, sintetske biomolekule, vitamini, lijekovi, ifosfonati, biološki aktivni ioni, fluorid, te markerske biomolekule.
when R1 represents 4-methoxyphenyl, then R2 does not represent 4-chlorophenyl or unsubstituted phenyl; 
kada R1 predstavlja 4-metoksifenil, tada R2 ne predstavlja 4-klorofenil ili nesupstituirani fenil;
A pharmaceutical composition comprising an antibody according to any one of claims 1-18 or 22-30 and/or a conjugate of claim 31, and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo sukladno patentnom zahtjevu 1 i/ili konjugat sukladno patentnom zahtjevu 3 i farmaceutski prihvatljiv nosač.
In one embodiment, the germinative compound is an amino acid selected from the group consisting of L-alanine, L-valine, L-proline, L-leucine, L-cysteine, L-threonine, L-glutamine, L-asparagine, and L-phenylalanine. 
Smjesa sukladno zahtjevu 1, naznačeno time, da je L-aminokiselina odabrana iz skupine koju čini L-alanin, I- valin, L-prolin, L-leucin, L-cistein, L-treonin, L-glutamin, L-asparagin, L-fenilalanin i njihovih analog.
to 50 wt.%, particularly 10 to 35 wt.% and preferably 15 to 25 wt.% of said ion-exchange resin; 
do 50 masenih %, posebno 10 do 35 masenih % i poželjno 15 do 25 masenih % navedene smole ionske izmjene;
a three-way solenoid valve (EV 5) on the return line (12 ″) of the primary hydraulic circuit (12), downstream of said heat exchanger (SC), 
trokraki solenoidni ventil (EV5) na povratnoj liniji (12") primarnog hidrauličkog kruga (12), iza izmjenjivača topline (SC), *
A biodegradable cigarette filter tow comprising composite filaments of cellulose and cellulose acetate, wherein the composite filaments are either fibres spun from a dope comprising cellulose and cellulose acetate, or shredded films cast from a similarly constituted dope. 
Uporaba kompozitnih filamenata celuloze i celuloznog acetata radi formiranja vlakna poboljšane biorazgradivosti u usporedbi s vlaknom koje se formira iz filamenata koji sadrže samo celulozu ili celulozni acetat, naznačena time, što se kompozitni filamenti ispredaju iz smjese koja sadrži celulozu i celulozni acetat.
a controller (MCM) being arranged to control the operation of the remote meter (RM) relating to 
- upravljačkog sklopa (MCM) koji je organiziran tako da upravlja operacijama na daljinskim brojačima (RM) vezano uz
Venlafaxine hydrochloride has a high solubility in water. 
Venlafaksin-hidroklorid je visoko topiv u vodi.
The polymorph Form II according to claim 1, which shows an X-ray powder diffraction pattern having the following characteristic peaks expressed in degrees 2θ ± 0.2 Degrees 2-Theta Relative intensity (%) 
Polimorfni Oblik II u skladu s patentnim zahtjevom 1, naznačen time što pokazuje uzorak difrakcije rendgenskih zraka na prahu koji imaju sljedeći karakteristične signale, izražene u stupnjevima 2θ ± 0,2 [image]
The process of any one of items 27 to 31, wherein the curing step c) takes place in a bed of free flowing extended release matrix formulations. 
Postupak prema bilo kojem zahtjevu od 27 do 31, naznačen time da se korak stvrdnjavanja c) odvija u sloju formulacija matrice s produljenim otpuštanjem koje se slobodno kreću .
is selected from the group consisting of NH and N-CH2-(phenyl optionally substituted with 1 to 5 substituents independently selected from the group consisting of C1-4 alkyl, C1-4 alkoxy, C1-9 amino, C1-8 alkylamino, C1-5 oxycarbonyl, cyano, halo, hydroxy, nitro, and trifluoromethyl) and X6 is selected from the group consisting of CH and CR4. 
-10 heteroaril po izboru supstituiran s 1 do 3 supstituenata na ugljiku koji su neovisno odabrani iz skupine koju čine amino, C1-8 alkilamino, C1-9 amid, C1-4 alkil, C1-4 alkoksi, cijano, halo, hidroksil, okso, trifluorometil, i trifluorometoksi, te po izboru supstituiran na dušiku u prstenu s C1-4 alkilom; i
Typically the additional active compound (c) is selected from the group consisting of (a) PDE IV inhibitors and (b) cortiocosteroids. 
Obično je dodatni djelatni spoj (c) odabran iz skupine koja se sastoji od (a) inhibitora PDE IV i (b) B2 agonista.
In a further embodiment of one of the methods described above folinic acid at a dosage of about 400 mg/m2, 5-fluorouracil (5-FU) at a dosage of about 2800 mg/m2, irinotecan at a dosage of about 180 mg/m2 and aflibercept at a dosage of about 4 mg/kg are administered to patient. 
Aflibercept za uporabu u liječenju pacijenta prema bilo kojem od patentnih zahtjeva 1 do 7 19 do 12, naznačen time što se pacijentu daju folinska kiselina u dozi od 400 mg/m', 5-fluorouracil (5-FU) u dozi od 2800 mg/m', irinotekan u dozi od 180 mg/m' i aflibercept u dozi od 4 mg/kg.
The integrated circuit according to claim 1, comprising: 
Integrirani krug sukladno zahtjevu 1, naznačen time da je broj veličina grupe bloka resursa.
The vaccine composition according Claim 1 wherein the homogenous mix of the conjugated hrEGF-rP64K additionally contains an appropriate adjuvant, selected from the group comprising aluminum hydroxide or Montanide. 
Sastav cjepiva prema zahtjevu 2, naznačen time, da homogena mješavina konjugirane hrEGF-rP64K dodatno sadrži prikladan adjuvans, odabran iz skupine koja sadrži aluminijev hidroksid ili Montanid.
The catheter as claimed in any preceding claim, wherein the valve comprises flaps(9) and the flaps are formed from as elastic material. 
Kateter prema bilo kojem od prethodnih zahtjeva, pri čemu ventil sadrži klapne (9) i te klapne su napravljene od elastičnog materijala.
The compound of any one of claims 1, 2 or 5, which is 
Spoj bilo kojeg od patentnih zahtjeva 1,2 ili 5, koji je
comparing the detected level of JCV antibody in the pre-incubated biological sample to the level of JCV antibody detected in a biological sample obtained from the subject that was pre-incubated in a solution without HPVLPs, and was contacted with HPVLP immobilized on a solid substrate under conditions suitable for binding of a JCV antibody in the sample to an HPVLP, wherein the HPVLPs are composed of more than 5, at least 50, 150 or 360 VP1 polypeptides. 
(d) uspoređivanju detektirane razine protutijela protiv JCV u predinkubiranom biološkom uzorku s razinom protutijela protiv JCV detektiranom u biološkom uzorku dobivenom iz subjekta predinkubiranom u otopini bez HPVLP-a, te stavljenom u kontakt s HPVLP imobiliziranim na čvrsti supstrat u uvjetima pogodnim za vezanje protutijela protiv JCV u uzorku na HPVLP, gdje se HPVLP-i sastoje od više od 5, najmanje 50, 150 ili 360 polipeptida VP1.
The method according any one of the preceding embodiments, wherein the removal of acidic ions comprises the steps of inserting the starting liquid into the chamber for the starting liquid; and inserting a dialysis liquid in the two further chambers for the dialysis liquid; and 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time što uklanjanje kiselih iona obuhvaća korake 1. - umetanje početne tekućine u komoru za početnu tekućinu; i II. umetanje tekućine za dijalizu u dvije daljnje komore za tekućinu za dijalizu; i
Pressurized air from compressor 50 is allowed to travel to nozzle 12. 
Zrak pod tlakom iz kompresora može teći do mlaznice 12.
A process to make fusidic acid cream as claimed in any of claims 9 and 10 further wherein a chelating agent is added to the step a of claim 9, said chelating agent being selected from a group comprising Disodium EDTA and the like, either singly or any combination thereof, from about 0.01 % (w/w) to 1% (w/w), preferably 0.5% (w/w), more preferably 0.1 % (w/w). 
Postupak za proizvodnju kreme s fusidinskom kiselinom prema bilo kojem od patentnih zahtjeva 9 1 10, naznačen time, da se nadalje agens za keliranje dodaje u stupnju a patentnog zahtjeva 9, a navedeni se agens za keliranje odabire iz skupine koja sadrži dinatrijevu EDTA 1 slične, ili pojedinačno ili bilo koju njihovu kombinaciju, od oko 0,01% (tež.) do 1% (tež.), prvenstveno 0,5% (tež.), pogodnije 0,1% (tež.).
ability to self-renew or proliferate; 
sposobnost samoobnavljanja ili proliferacije;
Awing according to claim 12, wherein the neutral aerofoil section and/or the reflexed camber aerofoil section are under cambered aerofoil sections, a concave shape of the aerofoil segment in which the under camber is assumed becoming increasingly tighter as the aerofoil section progressively deforms from the neutral camber aerofoil section to the reflexed camber aerofoil section, the concave shape being formed within or near a zone of maximum thickness of the aerofoil section. 
Krilo sukladno zahtjevu 12, pri čemu je neutralni dio zračnog profila i/ili refleksni nagib zračnog profila su pod nagibnim dijelovima zračnog profila, pri čemu je konkavni oblik segmenta zračnog profila za koji se pretpostavlja da je nagib sve jači kada se dio zračnog profila progresivno deformitra iz neutralnog nagiba dijela zračnog profila prema refleksnom dijelu pregiba zračnog profila, pri čemu je konkavni oblik oblikovan unutar ili blizu zone maksimalne debljine dijela zračnog profila ili u njenoj blizini.
Both E and Z isomers are embraced by the term “alkenyl.” 
Oba izomera E i Z su obuhvaćeni pojmom" alkenil".
The process according to claim 5, characterised in that the total amount of the at least one dispersing agent added before grinding step c), or before and during step c), or before and during and/or after grinding step c), is from about 0.01 to 1.25 wt%, preferably 0.05 to 1 wt%, more preferably 0.1 to 0.7 wt%, most preferably 0.3 to 0.5 wt% based on the dry weight of the mineral material. 
Postupak prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da ukupna količina barem jednog sredstva za raspršivanje dodanog prije koraka mljevenja c), ili prije i tijekom koraka c), ili prije i tijekom i/ili nakon koraka mljevenja c), je od oko 0.01 do 1.25 wt%, poželjno 0.05 do 1 wt%, još poželjnije 0.1 do 0.7 wt%, najpoželjnije od 0.3 do 0.5 wt% zasnovano na suhoj masi mineralnog materijala.
A compound according to claim 1, or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a condition or disorder selected from the group consisting of obesity, diabetes, anorexia nervosa, bulimia, cachexia, syndrome X, insulin resistance, hypoglycemia, hyperglycemia, hyperuricemia, hyperinsulinemia, hypercholesterolemia, hyperlipidemia, dyslipidemia, mixed dyslipidemia, hypertriglyceridemia, nonalcoholic fatty liver disease, atherosclerosis, arteriosclerosis, acute heart failure, congestive heart failure, coronary artery disease, cardiomyopathy, myocardial infarction, angina pectoris, hypertension, hypotension, stroke, ischemia, ischemic reperfusion injury, aneurysm, restenosis, vascular stenosis, skin cancer, melanoma, lymphoma, breast cancer, lung cancer, colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, prostate cancer, kidney cancer, liver cancer, bladder cancer, cervical cancer, uterine cancer, testicular cancer, ovarian cancer, and acne vulgaris. 
agonisti receptora peroksiznih proliferativnih aktivatora. Spoj prema bilo kojem zahtjevu 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se koristi kao lijek. Spoj prema bilo kojem zahtjevu 1 do 7, ili njegova farmaceutski prihvatljiva sol, naznačen(a) time, da se koristi u liječenju pretilosti, dijabetesa, bulimije, sindroma X, inzulinske rezistencije, hipoglikemije, hiperglikemije, hiperurikemije, hiperinzulinemije, hiperkolesterolemije, hiperlipidemije, dislipidemije, miješane dislipidemije, hipertrigliceridemije, pankreatitisa i ne-alkoholne bolesti masne jetre, ateroskleroze, arterioskleroze, akutne srčane isuficijencije, kongestivne srčane isuficijencije, koronarne arterijske bolesti, kardiomiopatije, miokardijskog infarkta, angine pektoris, hipertenzije, hipotenzije, udara, ishemije, ishemijske reperfuzijske ozljede, aneurizma, restenoze i vaskularne stenoze.
The mixture was cooled to room temp and concentrated. 
Smjesa je hlađena do sobne temperature i koncentrirana.
In at least one embodiment, the alkyl group may be chosen from methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and n-hexyl. The alkenyl group may be chosen from allyl, 2-butenyl, and 3-hexenyl. 
Lipidni spoj prema zahtjevu 1, pri čemu je alkil skupina, iz definicije za R2 i Rs, odabrana od metila, etila, n- Žž, propila, izopropila, n-butila, sec-butila i n-heksila.
In another embodiment, at least a particular percentage by weight of the compound of formula (II) is crystalline Form II. 
PATENTNI ZAHTJEVI Spoj predstavljen slijedećom strukturnom formulom: gdje je barem 50% po masi spoja kristalno.
a Bose-Chadhuri-Hocquenghem (BCH) encoder to BCH encode the PLP data; a Low Density Parity Check (LDPC) encoder to LDPC encode the BCH encoded PLP data and output Forward Error Correction Frames (FECFrames); 
sredstva (702-0) za vanjsko kodiranje PLP podataka; sredstva (303) za provjeru parnosti niske gustoće (eng. Low Density Parity Check, LDPC), koja kodiraju vanjski kodirane PLP podatke za unaprijedno ispravljanje pogrešaka i izlaz, okvir za unaprijedno ispravljanje pogrešaka (eng. forward error correction Frame, FECFrame) za LDPC kodirane PLP podatke;
The receiver unit is shown in FIG. 2 . 
Jedinica prijemnika je prikazana na slici 2.
The facility according to claim 6, wherein the drive device of the energy installation is operable with pure oxygen as an oxidizing agent. 
Postrojenje u skladu s patentnim zahtjevom 22, naznačeno time što pogonski uređaj (C11) energetskog pogona (C) može raditi s čistim kisikom (M31) kao oksidacijskim sredstvom.
[Summary of the invention] 
INTELEKTUALNO VLASNIÅ TVO dokumenta:
The combination for use according to claim 1 or 2, wherein insulin glargine or/and a pharmaceutically acceptable salt thereof is administered subcutaneously. 
Kombinacija namijenjena upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačena time što se inzulin glargin ili/i njegova farmaceutski prihvatljiva sol primjenjuje potkožno.
wherein the enzyme is adapted to enantioselectively hydrolyze the compound of Formula 4 to the compound of Formula 3 or a salt thereof; 
HR P20100054 TI gdje enzim je prilagođen tako da enantioselektivno hidrolizira spoj Formule 4 u spoj Formule 3, ili njegovu sol;